Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Glycobiology ; 17(6): 620-30, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17374617

RESUMO

In human pancreatic adenocarcinoma, alterations of glycosylation processes leads to the expression of tumor-associated carbohydrate antigens, representing potential targets for cancer immunotherapy. Among these pancreatic tumor-associated carbohydrate antigens, the J28 glycotope located within the O-glycosylated mucin-like C-terminal domain of the fetoacinar pancreatic protein (FAPP) and expressed at the surface of human tumoral tissues, can be a good target for anticancer therapeutic vaccines. However, the oncodevelopmental self character of the J28 glycotope associated with the low immunogenicity of tumor-associated carbohydrate antigens may be a major obstacle to effective anti-tumor vaccine therapy. In this study, we have investigated a method to increase the immunogenicity of the recombinant pancreatic oncofetal J28 glycotope by glycoengineering Galalpha1,3Galss1,4GlcNAc-R (alphaGal epitope) which may be recognized by natural anti-alphaGal antibody present in humans. For this purpose, we have developed a stable Chinese hamster ovary cell clone expressing the alphaGal epitope by transfecting the cDNA encoding the alpha1,3galactosyltransferase. These cells have been previously equipped to produce the recombinant O-glycosylated C-terminal domain of FAPP carrying the J28 glycotope. As a consequence, the C-terminal domain of FAPP produced by these cells carries the alphaGal epitope on oligosaccharide structures associated with the J28 glycotope. Furthermore, we show that this recombinant "alpha1,3galactosyl and J28 glycotope" may not only be targeted by human natural anti-alphaGal antibodies but also by the mAbJ28, suggesting that the J28 glycotope remains accessible to the immune system as vaccinating agent. This approach may be used for many identified tumor-associated carbohydrate antigens which can be glycoengineered to carry a alphaGal epitope to increase their immunogenicity and to develop therapeutic vaccines.


Assuntos
Antígenos Heterófilos/química , Antígenos de Neoplasias/química , Epitopos/química , Glicoproteínas/química , Engenharia de Proteínas , Adenocarcinoma/química , Adenocarcinoma/enzimologia , Adenocarcinoma/imunologia , Animais , Anticorpos Monoclonais/imunologia , Antígenos Heterófilos/genética , Antígenos Heterófilos/imunologia , Antígenos de Neoplasias/imunologia , Antígenos Glicosídicos Associados a Tumores/química , Antígenos Glicosídicos Associados a Tumores/imunologia , Células CHO , Células Clonais , Cricetinae , Cricetulus , DNA Complementar , Epitopos/imunologia , Galactosiltransferases/genética , Galactosiltransferases/imunologia , Humanos , Neoplasias Pancreáticas/química , Neoplasias Pancreáticas/enzimologia , Neoplasias Pancreáticas/imunologia , Proteínas Recombinantes/química , Proteínas Recombinantes/imunologia , Transfecção
2.
Mol Carcinog ; 42(4): 202-12, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15761838

RESUMO

The alphaGal epitope is a carbohydrate structure, Galalpha1,3Galbeta1,4GlcNAc-R, synthesized on glycoconjugates in many mammals by alpha1,3galactosyltransferase. Humans do not express this epitope and present in serum large amounts of naturally occuring antibodies, which recognize the alphaGal epitopes and participate in the hyperacute rejection of xenograft. Studies indicated that the fundamental mechanism of hyperacute rejection involving the alphaGal epitope expression can be used in cancer therapy. We have previously suggested that the alphaGal epitope expression by human pancreatic tumoral cells could decrease the tumorigenic behavior of these cells. To determine whether the expression of the alphaGal epitope can modify the tumorigenicity of pancreatic cancer cells, we used a Syrian golden hamster pancreatic adenocarcinoma experimental model. The expression of alphaGal epitopes in the Syrian golden hamster pancreatic cancer cell line HaP-T1 was obtained by selecting stable cell clones transfected with murine alpha1,3galactosyltransferase gene. The alphaGal epitope expression resulted in a delay in the tumoral development of HaP-T1 cells in vivo after allograft transplantation of Syrian golden hamsters (2.5-fold, P < 0.05) and of nude mice. This result is associated with an 100% increase in survival time of nude mice bearing tumors expressing the alphaGal epitope. Our results confirm that the cell surface expression of alphaGal epitope decreases the tumorigenic behavior of pancreatic cancer cells. This novel property may be useful for the development of cancer gene immunotherapy strategy.


Assuntos
Adenocarcinoma/genética , Dissacarídeos/genética , Neoplasias Pancreáticas/genética , Adenocarcinoma/patologia , Animais , Linhagem Celular Tumoral , Cricetinae , Modelos Animais de Doenças , Epitopos/genética , Galactosiltransferases/metabolismo , Humanos , Cinética , Mesocricetus , Neoplasias Pancreáticas/patologia , Plasmídeos , Valores de Referência , Transfecção
3.
Structure ; 12(8): 1437-47, 2004 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-15296737

RESUMO

Structure similarity searches using a combinatorial extension approach revealed that a protein fold structurally related to the sphingolipid binding domain (SBD) of HIV-1 gp120 (V3 loop) is present on pancreatic bile salt-dependent lipase (BSDL). A synthetic peptide derived from the predicted V3-like domain of BSDL interacted with reconstituted monolayers of sphingolipids such as GalCer and GlcCer. Using Chinese hamster ovary cells stably transfected with the cDNA encoding the rat BSDL (CHO-3B clone) or pancreatic SOJ-6 cells expressing the human BSDL as models, we showed that the enzyme cofractionates with caveolin-1. The secretion of BSDL by CHO-3B cells was inhibited by permeable drugs affecting rafts structure (D609, PDMP, and filipin). Data suggest that the functional interaction between the BSDL SBD and lipid rafts is physiologically relevant and could be essential for sensing the BSDL folding prior to secretion. A tentative model accounting for the phosphorylation-induced dissociation of BSDL from rafts is presented.


Assuntos
Exocitose/fisiologia , Microdomínios da Membrana/metabolismo , Modelos Moleculares , Esfingolipídeos/química , Esterol Esterase/metabolismo , Sequência de Aminoácidos , Animais , Hidrocarbonetos Aromáticos com Pontes/farmacologia , Células CHO , Caveolina 1 , Caveolinas/metabolismo , Clonagem Molecular , Cricetinae , Cricetulus , Exocitose/efeitos dos fármacos , Filipina/farmacologia , Proteína gp120 do Envelope de HIV/genética , Dados de Sequência Molecular , Morfolinas/farmacologia , Norbornanos , Fosforilação/efeitos dos fármacos , Dobramento de Proteína , Ratos , Esterol Esterase/genética , Tiocarbamatos , Tionas/farmacologia
4.
Neoplasia ; 6(6): 713-24, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15720797

RESUMO

Feto-acinar pancreatic protein (FAPP) characterized by mAbJ28 reactivity is a specific component associated with ontogenesis and behaves as an oncodevelopment-associated antigen. We attempted to determine whether pancreatic tumoral SOJ-6 cells are expressed at their surface FAPP antigens and to examine if specific antibodies directed against these FAPP epitopes could decrease the growth of pancreatic tumors in a mice model. For this purpose, we used specific antibodies against either the whole FAPP, the O-glycosylated C-terminal domain, or the N-terminal domain of the protein. Our results indicate that SOJ-6 cells expressed at their surface a 32-kDa peptide corresponding to the C-terminal domain of the FAPP. Furthermore, we show, by using endoproteinase Lys-C or geldanamycin, a drug able to impair the FAPP secretion, that this 32-kDa peptide expressed on the SOJ-6 cell surface comes from the degradation of the FAPP. Finally, an in vivo prospective study using a preventative tumor model in nude mice indicates that targeting this peptide by the use of mAb16D10 inhibits the growth of SOJ-6 xenografts. The specificity of mAb16D10 for pancreatic tumors and the possibility to obtain recombinant structures of mucin-like peptides recognized by mAb16D10 and mAbJ28 are promising tools in immunologic approaches to cure pancreatic cancers.


Assuntos
Anticorpos Monoclonais/farmacologia , Antígenos de Neoplasias/metabolismo , Lipase/imunologia , Lipase/metabolismo , Neoplasias Pancreáticas/imunologia , Neoplasias Pancreáticas/metabolismo , Animais , Western Blotting , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Eletroforese em Gel de Poliacrilamida , Citometria de Fluxo , Humanos , Camundongos , Camundongos Nus , Microscopia de Fluorescência , Transfecção , Transplante Heterólogo
5.
Int J Cancer ; 107(6): 910-8, 2003 Dec 20.
Artigo em Inglês | MEDLINE | ID: mdl-14601050

RESUMO

The enzyme alpha1,3galactosyltransferase synthesizes the alphaGal epitope, a carbohydrate structure (Galalpha1,3Galbeta1,4GlcNAc-R), on glycoconjugates in lower mammals. The enzyme is absent in humans but large amounts of natural antibodies that recognize alphaGal epitopes are present in human serum. It is likely that these antibodies contribute to the host defense and participate in the hyperacute rejection of xenograft. Previous studies indicated that the glycosyltransferase gene transfer into tumoral cells can modify the structure of glycoconjugates at the cell surface and, as a consequence, modulates the metastatic and tumorigenic behaviors of these cells. The aim of our study was to determine whether the expression of alphaGal epitope can modify the tumorigenicity of human pancreatic cancer cells. The expression of alphaGal epitopes in the human pancreatic cancer cell lines BxPC-3 and Panc-1 was obtained by selecting stable cell clones transfected with murine alpha1,3galactosyltransferase gene. The expression of the enzyme activity in BxPC-3 and Panc-1 cells resulted in the formation at the cell surface of alphaGal epitopes that are recognized by human anti-alphaGal antibodies. alphaGal epitope expression at the surface of pancreatic cancer cells was associated with the fixation of complement 1q to human anti-alphaGal antibodies. The alphaGal epitope expression also resulted in a delay in the tumoral development of BxPC-3 and Panc-1 cells in vivo after xenograft transplantation of nude mice. In addition to the impairment of the metastatic potential of murine tumor cell lines and the activation of immune response, our study provides evidence that the cell surface expression of alphaGal epitopes also modulates the tumorigenic behavior of human pancreatic cancer cells.


Assuntos
Galactosiltransferases/genética , Neoplasias Pancreáticas/enzimologia , Neoplasias Pancreáticas/patologia , Animais , Sequência de Bases , Divisão Celular , Primers do DNA , Epitopos/análise , Citometria de Fluxo , Galactosídeos/análise , Galactosiltransferases/metabolismo , Técnicas de Transferência de Genes , Humanos , Camundongos , Camundongos Nus , Plasmídeos , Proteínas Recombinantes/metabolismo , Transfecção , Transplante Heterólogo , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...